[6]Lara PN Jr, Laptalo L, Longmate J, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004 Jan;5(...
[14]Lara PN, Laptalo L, Longmate J, et al. Trastuzumab plus docetaxel in HER2/neu–positive non–small-cell lung cancer: a California cancer consortium screening and Phase II trial[J]. Clin Lung Cancer. 2004;5(4):231–236. [15]Mazier...
近期，一项研究[3]评估了ADC药物相比其他HER2靶向疗法针对HER2阳性局部晚期或转移性乳腺癌患者的生存获益，结果表明，ADC带来的无进展生存期（PFS）和总生存期（OS）改善具有统计学显著性，尤其是针对既往接受过抗HER2治疗的患者，再次验证了ADC药物在HER2阳性晚期乳腺癌中的治疗价值。现将研究主要内容梳理如下，以飨读者...
7、Krop IE,Kim S-B,González-Martín A,et al.Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer(TH3RESA):a randomised,open-label,phase 3 trial.Lancet Oncol.2014;15(7):689–699. 8、Hurvitz Sara A,Hegg Roberto,Chung Wei-Pang,et ...
在发现了neu之后,Weinberg教授并没有太在意它,当时,他的团队在努力攻坚RAS基因的克隆。这给了其他人一个机会,没过两年,就有几个不同团队的研究人员成功克隆出了HER2,测出了完整的序列,并确定了它位于17号染色体上[3,4,5]。 1987年,这也是乳腺癌治疗史上里程碑式的一年,加州大学洛杉矶分校的Dennis Slamon博士联...
2. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353:1652–4. 3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82. ...
[3]Sanford RA, Song J, Gutierrez-Barrera AM, et al. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors[J]. Cancer, 2015, 121(19):3422-3427. [4]Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Rec...
[7] National Institutes of Health. U.S. National Library of Medicine. ClinicalTrials. gov. Chemotherapy and lapatinib or trastuzumab in treating women with HER2/Neu-positive metastatic breast cancer. 2022. https://clinicaltrials.gov/ct2/show/results/NCT00667251. [Accessed 16 March 2022]. ...
[15]Llombart-Cussac A,et al.HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer(PAMELA):an open-label,single-group,multicentre,phase 2 trial.Lancet Oncol 2017;18:545–54. ...
28. Meric Bernstam F, Hainsworth J, Bose R, et al. MyPathway HER2 basket study: pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. J Clin Oncol. 2021;39 (suppl 15):3004. 10.1200/JCO.2021.39.15_suppl.3004...